BlackDoctor.org2h
Preparing for PrEP Side Effects
Like most prescribed medications, all three brands PrEP brands feature side effects. Here's how to prepare for them.
India Today on MSN2d
Bitten by a dog? Rabies vaccine is not enough, you need more to stay safe
In the event of a dog bite, a person needs more than just the rabies vaccine. Experts highlight the importance of ...
El Mundo on MSN2d
New advance against HIV: a single annual injection against the infection
Data from a very early-phase trial shows that the drug is safe and remains in the body for up to 56 weeks. From two ...
The Lancet3d
The potential for annual long-acting HIV pre-exposure prophylaxis
Pre-exposure prophylaxis (PrEP) is the advent of antiretroviral treatment use for people at increased risk of acquiring HIV-1 ...
PharmExec8h
Real-World Data Demonstrates Efficacy of Apretude and Cabenuva in HIV Prevention, Treatment
New real-world and implementation study data highlight the efficacy of ViiV’s long-acting injectables for HIV prevention and ...
The Washington Informer2d
Empowering Women and Girls: Advancing HIV Prevention
March is a significant month for women's health, observing International Women's Day and National Women's HIV/AIDS Awareness ...
STAT2d
Gilead data suggest once-yearly shot of PrEP drug blocks HIV infection
Gilead released data showing that an HIV drug, called lenacapavir, could provide virtually complete protection against ...
The American Journal of Managed Care1d
Long-Acting Injectable Cabotegravir Effective in Both ART, PrEP
Cabotegravir was found to prevent HIV acquisition as a monotherapy pre-exposure prophylaxis (PrEP) and to treat HIV as a ...
Medscape1d
Antiretrovirals Alone Don’t Delay Language Development in Exposed Children
Children exposed to antiretroviral (ARV) therapy in utero and not exposed to HIV showed no difference in language development at 5 years of age compared with unexposed children, based on new data from ...
Gilead presents data for once-yearly lenacapavir for HIV prevention
Sciences presented the first data from its ongoing Phase 1 study investigating two novel, once-yearly formulations of ...